Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved
Open Access
Abstract
This review aims to explore the role of immunotherapeutic strategies—primarily intravenous immunoglobulin (IVIG), plasma exchange (PLEX), and selected immunomodulatory agents—in the treatment of neurological and psychiatric disorders with suspected or confirmed autoimmune mechanisms. A central focus is placed on understanding the immunopathology of these conditions through the identification and characterization of disease-associated autoantibodies. Disorders such as autoimmune encephalitis, myasthenia gravis, limbic epilepsy, neuropsychiatric systemic lupus erythematosus (NPSLE), and certain forms of schizophrenia have shown clinical responses to immunotherapy, suggesting an underlying autoimmune basis in a subset of patients. The review also highlights the diagnostic relevance of detecting autoantibodies targeting neuronal receptors, such as NMDA and AMPA receptors, or neuromuscular junction components, as biomarkers that guide therapeutic decisions. Furthermore, we synthesize findings from published randomized controlled trials (RCTs) that have validated the efficacy of IVIG and PLEX in specific diseases, such as Guillain–Barré syndrome, and myasthenia gravis. Emerging clinical evidence supports expanding these treatments to other conditions where autoimmunity is implicated. By integrating immunological insights with clinical trial data, this review offers a comprehensive perspective on how immunotherapies may be tailored to target autoimmune contributors to neuropsychiatric disease.Keywords
All Related Versions
This publication has 125 references indexed in Scilit:
- If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndromeAnnals of Clinical and Translational Neurology, 2025
- Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort studyJournal of Neurology, 2023
- Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkersJournal of Neurology, 2020
- Self-reported disease severity in women with systemic lupus erythematosusRheumatology International, 2018
- Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patientsAnnals of Neurology, 2017
- Epstein–Barr virus strains and variations: Geographic or disease‐specific variants?Journal of Medical Virology, 2016
- Intravenous immunoglobulin for Guillain-Barré syndromeCochrane Database of Systematic Reviews, 2014
- Intravenous immunoglobulin for myasthenia gravisCochrane Database of Systematic Reviews, 2012
- Intravenous immunoglobulins for multiple sclerosisCochrane Database of Systematic Reviews, 2003
- Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisMuscle & Nerve, 2002